Tempus AI (TEM) has highlighted a series of product announcements, including FDA clearance for tumor-only use of its xT CDx platform and new AI driven diagnostics that are drawing fresh investor attention.

These product updates and regulatory milestones have arrived alongside a volatile trading pattern, with a 1-day share price return of 4.62% and 7-day share price return of 14.34%. The year-to-date share price return is down 15.33%, and the 1-year total shareholder return is down 16.81%, suggesting that recent momentum is building after a weaker stretch.

If this kind of healthcare AI story interests you, it can be useful to see what else is moving in the sector and compare business models across 40 healthcare AI stocks.

With Tempus AI trading at US$52.80 and flagged as trading at a discount to some analyst and intrinsic value estimates, the key question is whether that gap reflects mispricing or whether the market is already accounting for future growth.

Most Popular Narrative: 21.4% Undervalued

Compared with the last close at $52.80, the most followed narrative pegs Tempus AI's fair value at $67.20, which suggests a meaningful gap that depends on how its data platform and diagnostics scale from here.

Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage.

Expanding clinical-genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long-term growth opportunities.

Want to see what underpins that higher fair value? The narrative focuses on compounding revenue, rising margins and a future earnings multiple usually associated with sector leaders.

Result: Fair Value of $67.20 (UNDERVALUED)

However, this depends on Tempus AI managing rising competition in genomics and AI diagnostics, and on new assays securing reimbursement without putting pressure on margins.

Next Steps

Seeing both risks and rewards in the story so far, it makes sense to look at the underlying data yourself and move quickly to form an independent view with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you could miss companies that better match your goals, so take a few minutes to scan broader opportunities and pressure test your thinking.

• Spot potential bargains early by running through the screener containing 22 high quality undiscovered gems that match strong fundamentals with quieter market attention.
• Strengthen your core holdings with the solid balance sheet and fundamentals stocks screener (45 results) to focus on companies with sturdier financial foundations.
• Dial down portfolio swings by checking the 62 resilient stocks with low risk scores that stand out for more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.